Considering our result and the previous studies [20,21] that KRAS mutations often coexisted with PIK3CA mutations, inhibiting the PIK3CA signaling pathway might be a useful therapeutic strategy to treat CRC patients with KRAS mutations. This evidence concerns the gene KRAS and colorectal carcinoma.